Signaling network analysis and drug repurposing for COVID-19 treatment based on transcriptional response of lung host cells

Fuhai Li, Andrew P. Michelson, Randi E. Foraker, Philip PaynearXiv 2020 · arXiv

Abstract

The COVID-19 pandemic necessitated rapid therapeutic discovery. This study utilizes transcriptional profiles from SARS-CoV-2 infected human lung epithelial cells (NHBE, A549_ACE2, and Calu3) to identify dysfunctional signaling pathways. By clustering upregulated pathways into "super-GOs" and employing target-based and signature-based drug matching, the researchers identified potential repurposed medications. Key pathways included JAK-STAT and NFkB signaling. Notably, dexamethasone emerged as a top candidate, aligning with subsequent clinical trial successes.

Introduction

Early in the pandemic, the lack of approved therapies led to a focus on drug repurposing. Traditional approaches often relied on phenotypic observations. This research instead analyzes the molecular signaling pathways hijacked by SARS-CoV-2 to identify drugs that can specifically inhibit these cascades. By understanding the "engine room" of the virus's interaction with host cells, researchers can more accurately predict which existing medications might be effective.

Methods

The study integrated several computational techniques to map the host cell response:

  1. Transcriptional Profiling: Analysis of RNA-seq data (GSE147507) from infected lung cells to see which genes were significantly up- or down-regulated.
  2. Signaling Network Analysis: Identification of activated pathways using the KEGG database and shortest-path algorithms to find the most impacted signaling routes.
  3. Super-GO Clustering: Using affinity propagation to group redundant Gene Ontology (GO) terms into 10 distinct "super-GOs," providing a cleaner set of signatures for drug matching.
  4. Drug Matching: Utilizing DrugBank for target-based matching and the Connectivity Map (CMAP) for signature-based matching to find drugs that reverse the infection's molecular profile.
Signaling network analysis of SARS-CoV-2 infected lung cells showing activated pathways and gene interactions.

Results

The analysis highlighted core inflammatory and growth pathways such as MAPK, JAK-STAT, NFkB, and TNF. These pathways are central to the "cytokine storm" observed in severe COVID-19 cases. By looking for commonalities across different cell lines, the researchers filtered out cell-specific noise to find the core molecular response to the virus.

A total of 220 drugs were identified as potential candidates. Dexamethasone was the most frequent hit in the super-GO analysis, appearing 17 times. This finding was particularly significant as it served as a powerful validation of the model; dexamethasone was later clinically proven to significantly reduce mortality in patients requiring respiratory support.

List of potential repurposed drugs identified through computational analysis, including many currently in clinical trials.

Of the drugs identified in the primary analysis, 31 were already in clinical trials at the time of the study, including tocilizumab and ruxolitinib. Other high-frequency candidates included hydrocortisone and atorvastatin, both of which have been investigated for managing COVID-19 complications.

Discussion and Limitations

While the computational model successfully identified clinically relevant drugs, it relies on in vitro data from lab-grown cells. The physiological response in a living patient (in vivo) may vary significantly. Furthermore, the model identifies drugs based on molecular signatures but does not account for drug toxicity, dosage, or administration routes. For instance, while certain chemotherapy drugs were identified as hits, their immunosuppressive properties might be counterproductive in a viral infection context. Future work aims to integrate patient-specific data to create a more comprehensive "interactome" of the infection.

Summary updated

Abstract

The Coronavirus Disease 2019 (COVID-19) pandemic has infected >5.5 million people globally and carries a relatively high mortality rate. Currently, there is no effective vaccine or therapy approved for the treatment COVID-19, though many such therapeutics are being evaluated in clinical trials. Using the unique profiles of altered gene expression found in NHBE, A549_ACE2 and Calu3 human lung epithelial cells after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, we conducted a computational analysis to identify dysfunctional signaling pathways within infected cells. Using these data, potential therapeutic targets were identified and matched with existing medications to develop a theoretical approach to pharmacologic repurposing and inform clinical trial decisions. Specifically, signaling pathways upregulated by SARS-CoV-2 infection and their associated gene ontologies (GOs) were extracted and clustered to generate 10 super-GOs. The genes associated with the identified signaling pathways and the super-GOs were used as gene signatures to identify drugs that can potentially inhibit these signaling cascades. In these results, interesting signaling pathways and GOs such as JAK-STAT, IRF7-NFkB signaling, and MYD88/CXCR6 immune signaling were identified. Many drugs were identified with downstream inhibition of these signaling pathways and GOs, and many of which are currently undergoing clinical trial evaluation. The analysis results can be potentially helpful to facilitate the future clinical trial design. Rigorous clinical trial and experimental validations are needed to validate these results, considering the limitation of pure computational data analysis based on the noisy and limited data. some of these drugs might have harmful effects and cautions.
BibTeX
@misc{li2020signaling,
  author = {Fuhai Li and Andrew P. Michelson and Randi E. Foraker and Philip Payne},
  title = {{Signaling network analysis and drug repurposing for COVID-19 treatment based on transcriptional response of lung host cells}},
  year = {2020},
  eprint = {2006.01226},
  archivePrefix = {arXiv},
  url = {https://arxiv.org/abs/2006.01226},
}
Figure